These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29246084)

  • 1. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
    Capetti AF; Cossu MV; Paladini L; Rizzardini G
    Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
    Capetti AF; Astuti N; Cattaneo D; Rizzardini G
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
    Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
    van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
    Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
    Boswell R; Foisy MM; Hughes CA
    Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
    Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
    Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
    Ribera E
    AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.
    Properzi M; Magro P; Castelli F; Quiros-Roldan E
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):877-887. PubMed ID: 30392419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
    Gantner P; Cuzin L; Allavena C; Cabie A; Pugliese P; Valantin MA; Bani-Sadr F; Joly V; Ferry T; Poizot-Martin I; Garraffo R; Peytavin G; Fafi-Kremer S; Rey D;
    HIV Med; 2017 Oct; 18(9):704-708. PubMed ID: 28444816
    [No Abstract]   [Full Text] [Related]  

  • 13. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir-rilpivirine coformulation.
    Sun HY; Chang SY; Hung CC
    Curr Opin HIV AIDS; 2018 Jul; 13(4):320-325. PubMed ID: 29553948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.
    Blair HA
    Drugs; 2018 Nov; 78(16):1741-1750. PubMed ID: 30406902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
    Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
    Riccardi N; Del Puente F; Taramasso L; Di Biagio A
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218821657. PubMed ID: 30798670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
    Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
    HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
    [No Abstract]   [Full Text] [Related]  

  • 19. Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
    Fida M; Mahmood M; Temesgen Z
    Drugs Today (Barc); 2020 Jun; 56(6):405-421. PubMed ID: 32525138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.
    Corado KC; Caplan MR; Daar ES
    Drug Des Devel Ther; 2018; 12():3731-3740. PubMed ID: 30464404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.